Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer.

ABSTRACT:

Introduction

Programmed death-ligand 1 (PD-L1) expression determined by immunohistochemistry is the most widely used biomarker for predicting response to immune checkpoint inhibitors. The characteristics of PD-L1 expression in tumor cells inside lymphovascular spaces are largely unknown. Although PD-L1 expression in circulating tumor cells within vascular spaces had been studied, results were conflicting due to lack of standardized PD-L1 expression assessment.

Methods

We investigated PD-L1 expression in lung cancer primary tumor tissue, lymphovascular tumor emboli, and lymph node metastasis using the standard PD-L1 immunohistochemistry 22C3 pharmDx assay. PD-L1 expression was scored in the primary tumor, lymphovascular emboli, and lymph node metastasis by a pathologis

SUBMITTER: Yeh YC 

PROVIDER: S-EPMC9250021 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature